DEF: Ventyx Biosciences Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Ventyx Biosciences announces its 2025 annual meeting of stockholders to be held virtually on June 4, 2025, featuring proposals for director elections, executive compensation advisory vote, and ratification of the independent accounting firm.

Summary

• Ventyx Biosciences will hold its 2025 annual meeting of stockholders on June 4, 2025, at 10:00 am Pacific Time, conducted virtually.
• Stockholders of record as of April 10, 2025, are entitled to vote at the meeting.
• The meeting will address the election of two Class I directors for terms expiring in 2028.
• An advisory vote on the compensation of named executive officers for 2024 will be conducted.
• Stockholders will vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Proxy materials were first sent or given on April 23, 2025, and are accessible online.
• The board of directors recommends voting FOR the election of director nominees, FOR the advisory vote on executive compensation, and FOR the ratification of Ernst & Young LLP's appointment.

Sentiment

Score: 7

Explanation: The document is a standard corporate communication, presenting information in a neutral and professional tone. The positive score reflects the routine nature of the announcement and the company's efforts to engage with its shareholders.

Positives

• The board of directors is actively soliciting proxies to ensure stockholder representation at the annual meeting.
• Stockholders have multiple options for voting, including online, telephone, and mail.
• The company provides clear recommendations on how to vote on each proposal.
• The meeting will be held virtually, allowing for broader participation.

Future Outlook

The document outlines the business to be conducted at the 2025 annual meeting and provides guidance on how stockholders can participate and vote.

Management Comments

• On behalf of our Board of Directors, we would like to express our appreciation for your continued support of and interest in Ventyx.
• Our board of directors believes that our current executive compensation program has been effective at linking executive compensation to our performance and aligning the interests of our executive officers with those of our stockholders.

Industry Context

This is a standard proxy statement for a publicly traded company, outlining corporate governance matters and seeking stockholder votes on key issues.

Comparison to Industry Standards

• The director compensation policy was developed with input from our compensation committees independent compensation consultant, AON/Radford, regarding practices and compensation levels at comparable companies.
• The Executive Severance Plan was developed with input from AON/Radford, regarding severance practices at comparable companies and is designed to attract, retain and reward senior level employees.

Management Changes

Related Party Transactions

• The document describes indemnification agreements with directors and executive officers.
• The document describes a consulting agreement and separation agreement with William Sandborn.
• The document describes a separation agreement with Martin Auster.
• The document describes an executive chairperson agreement with Sheila Gujrathi.

Stakeholder Impact

• Stockholders are asked to vote on key proposals that will impact the company's governance and executive compensation.
• The outcome of the votes will influence the composition of the board of directors and the company's relationship with its independent auditor.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its annual meeting on June 4, 2025.
• The company will disclose voting results on a Current Report on Form 8-K that we will file with the U.S. Securities and Exchange Commission, or SEC, within four business days after the meeting.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, directors, executive compensation, Ernst & Young, voting, governance, Ventyx Biosciences